Fig. 1.

Effect of etanercept on plasma tumor necrosis factor-α (TNF-α) and soluble fms-like tyrosine kinase-1 (sFlt-1) levels in normal pregnant (NP) and reduced uterine perfusion pressure (RUPP) rats. Treatment with TNF-α inhibitor, etanercept, blunted circulating levels of TNF-α in response to RUPP in pregnant rats (A). Etanercept significantly reduced circulating levels of sFlt-1 in RUPP pregnant rats (B). Mean arterial pressure (MAP) was significantly increased in response to RUPP. Treatment with etanercept had no effect on MAP in either NP or RUPP rats (C). Data were analyzed by ANOVA followed by Tukey's post hoc test and are shown as means ± SE.